white → yellow2 → brown2
dose.wiki is still in beta. Entries may contain inaccuracies and/or lack citations. See our docs for more info.
4-AcO-DET
4-Acetoxy-N,N-diethyltryptamine
Ethacetin, Ethylacybin, 4-Acetoxy-DET
4-AcO-DET is a synthetic psychedelic of the tryptamine classcitation needed, first synthesized by Albert Hofmann at the Sandoz laboratory in 1958. It is chemically related to psilocin and belongs to a series of substituted tryptamines that includes 4-AcO-MET and 4-AcO-DMT. Its effects are generally compared to those of psilocybin mushrooms. It remains a lesser-known research chemical, typically encountered as a slightly off-white powder and most commonly administered orally.
Dosage & Duration
Dosage
Doses are population estimates that vary widely between individuals.
Threshold2-5 mg
Light5-15 mg
Moderate15-20 mg
Strong20-35 mg
Heavy35+ mg
Duration
Onset20-60 minutes
Come Up1-1.5 hours
Peak1.5-3 hours
Offset1-2 hours
After Effects2-4 hours
Total4-7 hours
Subjective Effects
Legacy content. A statistically backed ontology from Mindstate Design Labs is coming soon.
Effects vary widely by individual, dose, and context.
Physical
Cognitive
Visual
Auditory
Adapted from the 4-HO-DET subjective effects documentation. 4-AcO-DET is the acetylated prodrug of 4-HO-DET and is reported to produce an effectively identical experience. Forked from Subjective Effect Documentation work by
Josie Kins August 2016.
Josie Kins August 2016.See also: Psychedelic Intensity Scale, Effects of psychedelics (visual, cognitive, miscellaneous)
Pharmacology
Pharmacodynamics
In HEK-cell assays expressing individual human serotonin receptors, 4-AcO-DET bound and activated 5-HT2A, 5-HT2C, and 5-HT1A receptors. It had the highest affinity and potency of these three at 5-HT2A (Ki 248 ± 26 nM; EC50 309 ± 97 nM) and produced 79.1% ± 4.7% of the 5-HT maximum in the study's IP-1 assay.1
These in-vitro results demonstrate intrinsic serotonergic activity of 4-AcO-DET, but they do not establish how much of the human effect is produced by the parent compound versus its O-deacetylated metabolite, 4-HO-DET.2
Pharmacokinetics
A 2024 metabolism study observed O-deacetylation of 4-AcO-DET to 4-HO-DET in pooled human liver S9 fractions and zebrafish larvae. The study identified four phase I and one phase II metabolite in the liver model and ten phase I and two phase II metabolites in zebrafish larvae; the assignments were tentative because reference standards for the metabolites were unavailable.citation needed Recombinant-enzyme experiments implicated CYP1A2, CYP2C8, CYP2C19, CYP2D6, and CYP3A4 in N-deethylation; several CYP isoforms in hydroxylation; and CYP2C9, CYP3A4, and FMO3 in N-oxide formation. These model-based results identify candidate pathways and analytical biomarkers, not human bioavailability, conversion rate, clearance, or half-life.2
Dangerous
Highest riskThese combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
Unsafe
AvoidThere is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
Caution
Use cautionThese combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
Tolerance
Tolerance timelines are rules of thumb, not exact schedules, and vary widely between individuals and use patterns.
Full Tolerance
4-AcO-DET can produce tolerance very soon after it is taken.citation needed
Baseline Reset
Approximately 7 days
Half Tolerance
Approximately 3 days
Cross Tolerance
Serotonergic psychedelics
Harm Potential
Addiction & Dependence
Psychological
Extremely Low4-AcO-DET is believed to be not habit-formingcitation needed, and the desire to use it may actually decrease with repeated use.
Psychosis Risk
Delusions are listed as a potential cognitive effect during intoxication, but no systematic data exists on intrinsic psychosis risk.
Seizure Risk
No intrinsic seizure risk has been documented for this substance.
History & Culture
4-AcO-DET was first synthesized in 1958 by Albert Hofmann at the Sandoz laboratories in Switzerland. Despite this early synthesis, the compound remained largely unexplored for decades and has accumulated very little documented history of human usage.citation needed…
Trip Reports
Loading related reports
Preparing section content
Still loading. Refresh if this section does not appear.
Legality
International
4-AcO-DET is not listed in the current schedules of the 1961 Single Convention or the 1971 Convention on Psychotropic Substances, or in Tables I and II of the 1988 Convention.
By Country
Illegal6
BelgiumIllegal (analog/blanket ban)4-AcO-DET falls within Annex IVa's generic tryptamine-derivative definition. Its N,N-diethyl substitution is permitted at R1 and R2, and its 4-acetoxy substituent is an OAc group permitted at R3 at any position on the indole six-membered ring. Annex IVa substances are nationally listed and subject to the Royal Decree's controlled-substance regime.
BrazilIllegalPortaria SVS/MS No. 344/1998, List F26
Brazil’s controlled-substances list places 4-acetoxy-N,N-diethyltryptamine in List F2. List F2 is the national list for psychotropic substances of proscribed use.
DenmarkIllegal (analog/blanket ban)Bekendtgørelse om euforiserende stoffer (BEK nr 405 af 26. marts 2026)7
4-AcO-DET is covered as an ester derivative of a controlled tryptamine-group substance. List B covers the tryptamine group, including compounds derived from hydroxytryptamine by alkyl substitution on the side-chain nitrogen, and the order includes simple psychoactive derivatives such as esters of listed substances. List B substances may only be used for medical and scientific purposes.
Controlled / restricted4
SwitzerlandRestrictedBetäubungsmittelverzeichnisverordnung (BetmVV-EDI, SR 812.121.11), Articles 1(1)–(2) and 2(2), Annex 6 Verzeichnis e, item 79; consolidated text applicable 13 March 20261819
4-AcO-DET is expressly named in the current binding Annex 6 Verzeichnis e schedule as a raw material/product with presumed narcotic-like effect. This is a distinct controlled-products category, not a Verzeichnis d designation. The schedule does not impose an unqualified possession prohibition, and authorization and conduct exceptions may apply.
Not scheduled1
References
Source Pages
Citations
- Pharmacologic Activity of Substituted Tryptamines at 5-HT2A, 5-HT2C, 5-HT1A Receptors and the Serotonin Transporter. pmc.ncbi.nlm.nih.gov (n.d.). https://doi.org/10.1124/jpet.122.0014541
- Metabolism and cytotoxicity studies of the two hallucinogens 1cP-LSD and 4-AcO-DET in human liver and zebrafish larvae models using LC-HRMS/MS and a high-content screening assay. universaar.uni-saarland.de (n.d.). https://doi.org/10.1016/j.jpba.2024.11618712
- Toad. (2001). 4-acetoxy-DET Primer. Entheogen Review, 10(3). https://erowid.org/chemicals/4_acetoxy_det/4_acetoxy_det_primer.shtml1
- Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances, Annex IVa. famhp.be (n.d.). https://www.famhp.be/sites/default/files/content/INSP/NARC/annex%20IV_non%20official%20consolidated%20version.pdf1
- Royal Decree of 6 September 2017 regulating narcotic and psychotropic substances, Annex IVa. ejustice.just.fgov.be (n.d.). https://www.ejustice.just.fgov.be/eli/arrete/2017/09/06/2017031231/justel1
- Portaria SVS/MS No. 344/1998, List F2. gov.br (n.d.). https://www.gov.br/anvisa/pt-br/assuntos/medicamentos/controlados/lista-substancias1
- Bekendtgørelse om euforiserende stoffer (BEK nr 405 af 26. marts 2026). retsinformation.dk (n.d.). https://www.retsinformation.dk/eli/lta/2026/405/pdf1
- Betäubungsmittelgesetz (BtMG) Anlage I. (2019). https://www.gesetze-im-internet.de/btmg_1981/anlage_i.html1
- Betäubungsmittelgesetz (BtMG) § 3 Erlaubnis. Bundesministerium der Justiz / gesetze-im-internet.de (n.d.). https://www.gesetze-im-internet.de/btmg_1981/__3.html1
- 危険ドラッグの成分４物質を新たに指定薬物に指定. (2022). https://www.mhlw.go.jp/stf/houdou/0000092698.html1
Further Reading
Article Status
Step 1 · Automated synthesisAn autonomous workflow built by Josie Kins compiled this article's foundation from information published across the web.
- Step 2 · First-pass review
A first pass manual review and edit of article prose and copy has been performed by subject-matter expert Lyrea. This does not guarantee factual accuracy. An additional human review for each of this article's citations is yet to be performed.
- Step 3 · Citation reviewPending
No one has reviewed this article's citations yet. That second pass checks each claim against the source it cites.
Recent changes8 human edits · latest
Times are UTCNewest first
1 August 2026
Lyrea · Updated the article
13 July 2026
Lyrea · Updated the article
24 January 2026
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Josie Kins · Updated the article · also 1,4-Butanediol, 1B-LSD, 1cP-AL-LAD and 573 more
Suggest an edit
Spotted a mistake, an outdated claim, or something missing from the 4-AcO-DET article? Send the editors a private note. Feedback lands in a moderation queue and is never shown on the site.
Wish to give generalised feedback? You can do so here.
